Skip to content

Individual pain management in day surgery

Targeted pain management based on patient specific risk assesment in ambulatory surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2015-004515-20-FI
Enrollment
60
Registered
2016-01-04
Start date
2015-12-31
Completion date
Unknown
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.1 Level: LLT Classification code 10054711 Term: Postoperative pain System Organ Class: 100000004863

Interventions

Trade Name: Lyrica Pharmaceutical Form: Capsule, hard INN or Proposed INN: PREGABALIN CAS Number: 148553-50-8 Other descriptive name: PREGABALIN Concentration unit: mg milligram(s) Concentration type

Sponsors

Vesa Kontinen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Laparoscopic cholecystectomy, age over 18 and under 70, ASA classification 1-2 , weight over 50 kg, willing to participate, able to use the NRS scale in the assessment of pain, finnish speaking. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0

Exclusion criteria

Exclusion criteria: Age under 18, age over 70, ASA classification 3-5, weight under 50 kg, BMI over 40 kg/m2, pregnancy, breastfeeding, allergy for pregabalin, current use of pregabalin or gabapentinoids, unable to use the NRS scale, not willing to participate, not able to give written consent.

Design outcomes

Primary

MeasureTime frame
Main Objective: Does pregabalin given based on the risk analysis on each patient reduce postoperative pain at 60 min after laparoscopic cholecystectomy.;Secondary Objective: Does pregabalin given based on the risk analysis on each patient reduce the consumption of analgesics and side effects after laparoscopic cholecystectomy;Primary end point(s): Postoperative pain.;Timepoint(s) of evaluation of this end point: 1 hour after the operation.

Secondary

MeasureTime frame
Secondary end point(s): Postoperative pain, consumption of analgesics, side effects as nausea, vomiting, dizziness, headache, drowsiness. ;Timepoint(s) of evaluation of this end point: On the operation day, firts postoperative day, third postoperative day, 1 month after the operation.

Countries

Finland

Contacts

Public ContactDay surgery unit

Helsinki University Hospital, Jorvi Hospital

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026